Hims & Hers Health Inc. plans to jump into the peptides market before the end of the year, with executives seeing opportunity to seize on a booming corner of the health industry.
Hims & Hers Health shares are down after the telehealth firm reduced the top end of its adjusted Ebitda forecast for the full year.
Telehealth companies including Hims & Hers and Noom have called on a panel of experts to recommend the legalization of several popular peptides. They emphasized the need for increased oversight and the establishment of a system to report side effects.
As Hims prepares for peptides launch, Wall Street cautious on prospects this year
Hims & Hers shares slide as costly weight-loss push squeezes margins
AST SpaceMobile, Intel, On, Hims, and More Stocks That Explain Today's Market
Hims & Hers Health Boosts Revenue Target, Swings to Second-Quarter Loss
Hims & Hers Shares Drop After Mixed Q2 Earnings — Details
Hims & Hers raises annual forecast revenue on strong subscriber growth
Hims & Hers Health Likely To Report Q2 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call